This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rahim, A. Articles by Shalet, S. M. Search for Related Content PubMed PubMed Citation Articles by Rahim, A. Articles by Shalet, S. M.

Growth Hormone Status during Long-Term Hexarelin Therapy

Department of Endocrinology (A.R., S.M.S.), Christie Hospital, Withington, Manchester, M20 4BX; and University Department of Geriatric Medicine (P.A.O.), South Manchester University Hospital Trust, Manchester, M20 8LR, United Kingdom

Address all correspondence and requests for reprints to: Professor S. M. Shalet, Department of Endocrinology, Christie Hospital National Health Service Trust, Wilmslow Road, Manchester M20 4BX, United Kingdom.

Hexarelin, a powerful GH-releasing peptide, is capable of causing profound GH release in normal subjects after oral, intranasal, iv, and sc administration. The effect of long-term administration on GH levels in adults is unknown. We have, therefore, assessed the effects of 16 weeks of twice-daily sc hexarelin therapy (1.5 µg/kg BW) on the GH response to a single injection of hexarelin, and also the GH response to hexarelin 4 weeks after cessation of hexarelin therapy. We have also assessed the effects of chronic hexarelin therapy on serum insulin-like growth factor (IGF)-I, IGF binding protein-3, markers of bone formation (osteocalcin, procollagen-type-III-N-terminal-peptide, and C-terminal propeptide of type I collagen), and resorption (urinary deoxypyridinoline and pyridinoline), body composition, and bone mineral density.

The mean (±SEM) area under the GH curve (AUC_GH) at weeks 0, 1, 4, 16, and 20 were 19.1 ± 2.4 µg/L·h, 13.1 ± 2.3 µg/L·h, 12.3 ± 2.4 µg/L·h, 10.5 ± 1.8 µg/L·h, and 19.4 ± 3.7 µg/L·h, respectively. There was a significant change in AUC_GH over the study period (P = 0.0003). Further analysis showed that, compared with baseline, the decrease in AUC_GH at week 4 and week 16 were significant (P < 0.05 and P < 0.01, respectively). Four weeks after completion of hexarelin therapy, the AUC_GH increased significantly, compared with AUC_GH at week 16 (P < 0.05), and was not significantly different from that at week 0.

Serum IGF-I and IGF binding protein-3 did not change significantly over the 20-week period (P = 0.24 and P = 0.74, respectively). Of the bone markers measured, only serum C-terminal propeptide of type I collagen changed significantly and was higher at week 16, compared with baseline (P = 0.019). Total body fat, lean body mass, and bone mineral density had not changed significantly at week 16, compared with baseline (P = 0.6, P = 0.3, and P = 0.3, respectively).

In summary, we have demonstrated that chronic hexarelin therapy results in a partial and reversible attenuation of the GH response to hexarelin. In the present study, the biological impact of this hexarelin schedule on the GH-IGF-I axis seems to be minimal. The therapeutic potential of chronic hexarelin requires further investigation.

This article has been cited by other articles:

				G. Fanciulli, A. Delitala, and G. Delitala Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone Hum. Reprod. Update, May 1, 2009; 15(3): 341 - 358. [Abstract] [Full Text] [PDF]

				H. K. White, C. D. Petrie, W. Landschulz, D. MacLean, A. Taylor, K. Lyles, J. Y. Wei, A. R. Hoffman, R. Salvatori, M. P. Ettinger, et al. Effects of an Oral Growth Hormone Secretagogue in Older Adults J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1198 - 1206. [Abstract] [Full Text] [PDF]

				C. Y. Bowers, R. Granda, S. Mohan, J. Kuipers, D. Baylink, and J. D. Veldhuis Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2290 - 2300. [Abstract] [Full Text] [PDF]

				A. Tivesten, E. Bollano, K. Caidahl, V. Kujacic, X. Y. Sun, T. Hedner, A. Hjalmarson, B.-A. Bengtsson, and J. Isgaard The Growth Hormone Secretagogue Hexarelin Improves Cardiac Function in Rats after Experimental Myocardial Infarction Endocrinology, January 1, 2000; 141(1): 60 - 66. [Abstract] [Full Text] [PDF]

				R. C. Jenkins, A. Meguid El Nahas, M. E. Wilkie, C. B. Brown, J. Jones, E. Ghigo, and R. J. M. Ross The Effects of Dose, Nutrition, and Age on Hexarelin-Induced Anterior Pituitary Hormone Secretion in Adult Patients on Maintenance Hemodialysis J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1220 - 1225. [Abstract] [Full Text]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]